Trial Profile

Ruxolitinib in Combination With Corticosteroid as First Line Therapy for the Treatment of High Risk Acute Graft-Versus-Host Disease

Status: Completed

Phase of Trial: Phase II

Latest Information Update: 30 Nov 2023

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Ruxolitinib (Primary) ; Methylprednisolone
Indications Graft-versus-host disease
Focus Therapeutic Use

Most Recent Events

25 Nov 2023 Status changed from recruiting to completed.
13 Dec 2022 Results assessing the safety and efficacy of corticosteroids (2mg/kg/day) alone versus ruxolitinb combined with reduced dose of corticosteroids (1mg/kg/day) in patients with high-risk aGVHD after allogeneic peripheral blood stem cell transplantation. presented at the 64th American Society of Hematology Annual Meeting and Exposition
06 Jun 2022 Trial design published in the Trials

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com